



8 June 2004

Leading Burns Surgeon to Conduct Animal Trials Using VitroGro®

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has accelerated its efforts to develop a treatment for human burns based on its proprietary VitroGro® technology with a new collaboration with leading Australian burns surgeons.

Chairman, Mr Roger Clarke advised today that Tissue Therapies has signed an agreement with UniQuest, the commercialisation arm of the University of Queensland.

He said the agreement enables the commencement of animal-based trials to develop VitroGro® products for more effective treatment of paediatric burns.

“Using pig models (the closest biological model to humans) the trials will assess the potential of VitroGro® as a treatment for paediatric burns,” he said.

“We expect the animal trials to commence within two months and continue for approximately 90 days.”

The animal trials will be managed by leading paediatric burns surgeon, Associate Professor Roy Kimble, based at the Royal Children’s Hospital in Brisbane.

Dr Kimble is Clinical Director of the Stuart Pegg Paediatric Burns Centre and Head of the Royal Children's Hospital Burns Research Group (a co-operative research team comprising staff of the Department of Paediatrics and Child Health, University of Queensland and the Royal Children's Hospital, Queensland Health).

Mr Clarke said Tissue Therapies was delighted to be able to augment its core team with the expertise of Dr Kimble and his colleagues via this new arrangement with UniQuest.

The ongoing VitroGro® R&D program is provided under a long-term agreement with QUT, which provides access to a team of tissue engineering experts, the majority of whom are shareholders in Tissue Therapies.

ENDS

Further information:

Dr Roy Kimble
royk@uq.edu.au

Dr Zee Upton
Chief Scientific Officer, Tissue Therapies Limited
Mobile: 0404 816 844
z.upton@tissuetherapies.com

Roger Clarke
Chairman, Tissue Therapies Limited
Telephone: 07 3334 4832

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and cell culture.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at Queensland University of Technology for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration and cell culture.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for research and industrial cell culture markets internationally.

Distributed by: Libby Baynton
NOUS Corporate
Tel: 0414 517 784
libby@nous.com.au

For more information: www.tissuetherapies.com